Tel-Aviv Sourasky MC

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Macular degeneration4 trials
• Hodgkin lymphoma3 trials
• Chronic lymphocytic leukaemia2 trials
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Diabetic eye disease1 trial
• Liver and biliary tract cancer1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 13 trials
• Phase 33 trials
• Phase 22 trials
• Phase 1/21 trial

Status

• Completed5 trials
• Active, not recruiting2 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Janssen Research & Development, LLC3 trials
• Genentech, Inc.1 trial
• HepaRegeniX GmbH1 trial
• Institute for Cardiovascular Diseases Dedinje1 trial

Running trials

• Recruiting

  Safety of HRX215 in Patients After Minor and Major Liver Resection

  NCT06638502· Phase 1/2· HepaRegeniX GmbH· Source

  Contact: Wolfgang Albrecht, PhD NC

• Recruiting

  Southeastern Europe Microcirculation Registry

  NCT06393478· Institute for Cardiovascular Diseases Dedinje· Source

  Contact: Maayan Konigstein, MD, PhD

• Recruiting

  A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

  NCT05626114· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting
• Coronary artery disease1 recruiting

Closed trials

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

  NCT05151744· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

  NCT03573310· Phase 1· Janssen Research & Development, LLC· Source